IL6 and breast cancer: Similar results showed that PSP treatment of the acute myeloid leukemia line, HL-60 resulted in a dose-dependent increase of IL-6 release (22), while 24-h treatment with PSP and PHA of human PBMCs from breast cancer patients also showed increased IL-6 expression (8).